Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
NCT ID: NCT05630768
Last Updated: 2025-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
149 participants
INTERVENTIONAL
2023-01-03
2025-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
NCT00632216
Satisfaction and Compliance of Risedronate in PMO
NCT00549965
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
NCT00919711
Risedronate Sodium in Post Menopausal Osteoporosis
NCT00453492
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
NCT01575873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Actonel®
Risedronate Sodium 35mg
Risedronate Sodium 35 MG [Actonel]
Risendronate Sodium Tab. 35mg, orally, once weekly
Calcium Vitamin D combination
orally, once daily for concomitant drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risedronate Sodium 35 MG [Actonel]
Risendronate Sodium Tab. 35mg, orally, once weekly
Calcium Vitamin D combination
orally, once daily for concomitant drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year
Exclusion Criteria
2. Those evaluated as inappropriate at the discretion of the investigator
50 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A ST Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATN_PMO_IV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.